Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 21/06/2024 BST 		5-day change 1st Jan Change
468.7 USD -0.57% Intraday chart for Vertex Pharmaceuticals Incorporated -2.50% +15.19%
06-21 Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes MT
06-21 Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes MT
Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes CI
Vertex Pharmaceuticals Has Pricing Accord for Cystic Fibrosis Drugs With UK National Health Service MT
Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465 MT
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials MT
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on CASGEVY (Exagamglogene Autotemcel) CI
Vertex Pharmaceuticals Insider Sold Shares Worth $1,089,840, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,483,664, According to a Recent SEC Filing MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM
RBC Adjusts Price Target on Vertex Pharmaceuticals to $421 From $424 MT
Vertex Pharmaceuticals Says Phase 3 Data Show Trikafta Improves Lung Function in Cystic Fibrosis Patients MT
Vertex Pharmaceuticals Incorporated Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA CI
Vertex Pharmaceuticals Insider Sold Shares Worth $1,495,000, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 04:00 PM
Vertex Pharmaceuticals Insider Sold Shares Worth $2,033,159, According to a Recent SEC Filing MT
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480 MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing MT
ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment MT
Vertex Pharmaceuticals Incorporated completed the acquisition of Alpine Immune Sciences, Inc. from a group of shareholders. CI
Declaration of Voting Results by Vertex Pharmaceuticals Incorporated CI
Declaration of Voting Results by Vertex Pharmaceuticals Incorporated CI

Chart Vertex Pharmaceuticals Incorporated

Chart Vertex Pharmaceuticals Incorporated
More charts

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
Biotechnology & Medical Research
Calendar
31/07/2024 - Q2 2024 Earnings Release (Projected)
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
468.7 USD
Average target price
463.4 USD
Spread / Average Target
-1.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.19% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.91% 114B
ARGENX SE Stock argenx SE
+8.24% 23.61B
BIONTECH SE Stock BioNTech SE
-19.80% 20.43B
GENMAB A/S Stock Genmab A/S
-16.19% 16.55B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.45% 16.45B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.35% 15.59B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+66.67% 15.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.13% 13.54B
INSMED INCORPORATED Stock Insmed Incorporated
+119.39% 10.96B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VRTX Stock
  4. News Vertex Pharmaceuticals Incorporated
  5. Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing